Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection by Single Intravenous Infusion in Healthy Chinese Subjects

NCT07057726 is registered in ClinicalTrials.gov with Shenyang Sunshine Pharmaceutical Co., LTD. as lead sponsor.

NCT NCT07057726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07057726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection by Single Intravenous Infusion in Healthy Chinese Subjects
Lead sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
October 9, 2024
Completion date
October 31, 2025
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety and tolerability in healthy volunteers